AstraZeneca withdraws US and EU filings for Zactima in lung cancer
This article was originally published in Scrip
Executive Summary
AstraZeneca has withdrawn the US and EU filings of its most advanced anticancer in development, the oral multi-targeted kinase inhibitor Zactima (vandetanib) after regulators failed to be impressed by its efficacy. It had hoped the drug would secure approval as a second-line therapy in non-small cell lung cancer (NSCLC).